

PRODUCT INFORMATION

Target CD19

Synonyms CD19,B4,CVID3,MGC12802

DescriptionRecombinant human CD19 Protein with C-

terminal 10×His tag

DeliveryIn StockUniprot IDP15391Expression HostHEK293

Tag C-10×His tag

Molecular Characterization

CD19(Pro20-Lys291) 10×His tag

Molecular Weight The protein has a predicted molecular mass of 31.5 kDa after removal of the signal peptide.

The purity of the protein is greater than 85% as determined by SDS-PAGE and Coomassie blue

staining.

Formulation & Reconstitution

Background

Purity

Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis

for specific instructions of reconstitution. Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not

Storage & Shipping

intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient

témperature.

This gene encodes a member of the

immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular lg-like domains separated by a non-lg-like domain, a hydrophobic

transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins

cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase


Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in

Email: info@dimabio.com Website: www.dimabio.com

bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]

Usage Research use only

Conjugate Unconjugated








Figure 1. Human CD19 Protein, His Tag on SDS-PAGE under reducing condition.

Email: info@dimabio.com Website: www.dimabio.com

